Yifeng Pharmacy: Executive Xiao Zaixiang reduces holdings by 60,000 shares, cashing out approximately 1,419,500 yuan

Yifeng Pharmacy (Stock Code: 603939) announced on March 6th that the implementation period of the company’s senior management share reduction plan has expired. According to the announcement, Vice President Xiao Zaixiang sold a total of 60,000 shares between December 8, 2025, and March 7, 2026, at prices ranging from 23.24 to 24.20 yuan per share, totaling 1,419,500 yuan. Another Vice President, Wang Yonghui, holds 601,440 shares of the company and did not sell any during this period.

The announcement states that due to market conditions and other factors, Wang Yonghui did not execute his original share reduction plan. This reduction was not subject to minimum share amount or percentage restrictions and complied with all relevant laws and regulations.

Tianyancha data shows that Yifeng Pharmacy was established on June 20, 2008, with a registered capital of approximately 1.2124 billion RMB. The legal representative is Gao Yi, and the registered address is No. 2638, Renmin Road, Fuqing Community, Baimahu Street, Wuling District, Changde City, Hunan Province. Its main business includes the retail of Chinese and Western patent medicines, Chinese herbal decoctions, medical devices, health foods, health products, personal care items, and daily necessities related to health, as well as household cleaning and other convenience goods through multiple channels.

Currently, the company’s chairman is Gao Yi, the secretary is Fan Wei, with 40,018 employees, and the actual controller is Gao Yi.

The company has investments in 21 subsidiaries, including Hunan Yifeng Pharmaceutical Co., Ltd., Jiangsu Yifeng Chain Pharmacy Co., Ltd., Hubei Yifeng Pharmaceutical Co., Ltd., Shijiazhuang Xinxing Pharmacy Chain Co., Ltd., Shaoguan Xiangqin Pharmacy Chain Co., Ltd., and others.

In terms of performance, the company’s revenue for 2022, 2023, and 2024 was 19.886 billion, 22.588 billion, and 24.062 billion RMB, respectively, with year-over-year growth of 29.75%, 13.59%, and 6.53%. Net profit attributable to shareholders was 1.266 billion, 1.412 billion, and 1.529 billion RMB, with year-over-year increases of 42.54%, 11.90%, and 8.26%. During the same period, the company’s asset-liability ratio was 56.64%, 56.72%, and 59.27%.